Furthermore, the combination of CCR2 (the receptor for CCL2) inhibition and anti-PD-1 therapy has been shown to enhance tumor responses over anti-PD-1 monotherapy through enhanced recruitment and activation of CD8+ T-cells47. This evidence concerns the gene PDCD1 and neoplasm.